Home » Stocks » CERE

Cerevel Therapeutics Holdings, Inc. (CERE)

Stock Price: $13.15 USD -0.27 (-2.01%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 1.72B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 127.12M
EPS (ttm) -27.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $13.15
Previous Close $13.42
Change ($) -0.27
Change (%) -2.01%
Day's Open 13.43
Day's Range 12.79 - 14.46
Day's Volume 227,460
52-Week Range 9.82 - 18.27

News

Hide News
GlobeNewsWire - 1 month ago

Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...

About CERE

Cerevel Therapeutics Holdings operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a P... [Read more...]

Industry
Biotechnology
Founded
2018
CEO
Dr. N. Anthony Coles Jr.
Employees
100
Stock Exchange
NASDAQ
Ticker Symbol
CERE
Full Company Profile

Analyst Forecasts

The average 12-month stock price forecast for CERE is 22.33, which is an increase of 69.81% from the latest price.

Price Target
$22.33
(69.81% upside)